KCM
PTCT icon

Kingdon Capital Management’s PTC Therapeutics PTCT Stock Holding History

Kingdon Capital Management’s Portfolio PTCT Stock Details PTCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-402,800
Closed -$3.96M – 127
2017
Q1 		$3.96M Buy
402,800
+202,800
+101% +$2.45M 0.22% 81
2016
Q4 		$2.18M Buy
+200,000
New +$2.1M 0.11% 110

Other funds holding PTCT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Kingdon Capital Management's PTCT Position: Q3 2020 in Review

Kingdon Capital Management sold out of PTC Therapeutics (PTCT) in Q3 2020, closing a stake of 251,734 shares — an estimated $12.8M sold.

Kingdon Capital Management first reported a position in PTCT in Q4 2016 and held it in 7 quarters. The position peaked at $12.8M in Q2 2020. 196 funds tracked by Wall St. Rank hold PTCT as of Q3 2020.

  • Kingdon Capital Management reported no remaining PTC Therapeutics position as of Q3 2020 after selling out during the quarter.
  • Kingdon Capital Management sold 251,734 PTC Therapeutics shares in Q3 2020, an estimated $12.8M.
  • Kingdon Capital Management first reported a position in PTC Therapeutics in Q4 2016 and held it in 7 quarters.
  • Kingdon Capital Management's PTC Therapeutics position peaked at $12.8M in Q2 2020.
  • 196 funds tracked by Wall St. Rank held PTC Therapeutics as of Q3 2020.

Based on Kingdon Capital Management's 13F filing for Q3 2020, filed 16 Nov 2020.